Nitric Oxide Is the Master Signal for Erection
An erection is fundamentally a vascular event. The penis contains two cylindrical chambers — the corpora cavernosa — filled with smooth muscle and vascular tissue. At rest, this tissue is contracted and blood flow is restricted. An erection occurs when smooth muscle relaxes, arterial inflow increases dramatically, and venous outflow is restricted, trapping blood in the chambers under pressure.
The molecule that triggers smooth muscle relaxation is nitric oxide (NO). Without adequate NO production, the vascular machinery of an erection cannot fire. This is not an auxiliary pathway — it is the central mechanism, and its impairment is the biochemical basis of most vasculogenic erectile dysfunction.
The NO Pathway Step by Step
Understanding the sequence helps clarify why different interventions work — and where they work:
- Arousal triggers neural release. Sexual stimulation activates nonadrenergic noncholinergic (NANC) neurons in the penis, which release nitric oxide directly into the smooth muscle of the corpora cavernosa.
- Endothelial cells amplify the signal. The endothelium — the inner lining of blood vessels — produces additional NO via the enzyme endothelial nitric oxide synthase (eNOS). This endothelial contribution sustains the erection beyond the initial neural trigger.
- NO activates cGMP production. Inside smooth muscle cells, NO activates the enzyme guanylate cyclase, which converts GTP into cyclic guanosine monophosphate (cGMP). cGMP is the direct mediator of smooth muscle relaxation.
- cGMP causes vasodilation and erection. High intracellular cGMP causes smooth muscle to relax, allowing cavernosal arteries to dilate and the corpora to fill with blood.
- PDE5 breaks down cGMP. The enzyme phosphodiesterase type 5 (PDE5) degrades cGMP, ending smooth muscle relaxation and allowing detumescence. In men with insufficient NO or overactive PDE5, this degradation terminates the erection prematurely — or prevents it entirely.
Why NO Production Declines
Endothelial dysfunction — impaired NO production by blood vessel lining — is the most common underlying cause of vasculogenic ED. The factors that drive endothelial dysfunction are largely the same as those that drive cardiovascular disease:
- Hypertension generates oxidative stress that consumes NO and damages eNOS
- Hyperglycemia and insulin resistance reduce eNOS activity and increase production of superoxide, which inactivates NO
- Hypercholesterolemia impairs endothelial function through plaque formation and oxidative mechanisms
- Tobacco use directly suppresses eNOS and accelerates endothelial aging
- Sedentary behavior removes the mechanical stimulus (shear stress from blood flow) that normally upregulates eNOS expression
- Aging decreases eNOS expression and increases oxidative inactivation of NO across all vascular beds
Dietary and Lifestyle Factors That Support NO Production
Several evidence-supported approaches can modestly increase NO bioavailability:
- Dietary nitrates (leafy greens, beets): Converted to nitrite then to NO via oral bacteria and gastric acid. High-nitrate diets are associated with improved endothelial function and modest blood pressure reduction.
- L-arginine: A precursor to NO synthesis via eNOS. Supplementation has marginal effects in men with normal endothelial function but may show more benefit where endothelial arginine transport is impaired. Doses used in trials are 3–6 g/day.
- L-citrulline: Converts to arginine more efficiently than oral arginine itself. Small RCTs show modest improvements in mild-to-moderate ED. Not a substitute for prescription therapy but a reasonable add-on.
- Aerobic exercise: The most evidence-backed intervention for improving endothelial NO production. Studies show 30–40 minutes of moderate aerobic exercise 4–5 days per week meaningfully improves erectile function scores over 12–16 weeks.
- Smoking cessation: Removes one of the most potent suppressors of eNOS activity. Erectile function improvements after cessation are well-documented, though vascular recovery is gradual over months to years.
How PDE5 Inhibitors Work Through This Pathway
PDE5 inhibitors — sildenafil, tadalafil, vardenafil, avanafil — do not generate NO. This is a common misconception. What they do is prevent PDE5 from breaking down cGMP, extending the downstream effects of whatever NO is produced. If NO production is severely impaired, they have limited effect. This is why PDE5 inhibitors require sexual stimulation to work and why they lose efficacy in men with advanced endothelial dysfunction or severe vascular disease.
Their mechanism also explains why daily low-dose tadalafil (5 mg) has both erectile and cardiovascular benefit — maintaining cGMP availability continuously supports vascular health beyond acute erectile response.
Evaluation for PDE5 inhibitor therapy, including daily and on-demand options, is available through Hard Health without an in-office visit.